RxDoctor Payments Data

Kylee Gatzke

Family · Cadillac, MINPI 1730431917

Payments from drug & device makers

$679in general payments, 2019–2025

Across 24 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$298
  • AbbVie$175
  • GSK$51
  • Otsuka America Pharmaceutical, Inc.$50
  • Amgen$30
  • Boston Scientific$24
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$298
AbbVie8$175
GSK2$51
Otsuka America Pharmaceutical, Inc.2$50
Amgen(2 entities)2$30
Boston Scientific1$24
Pfizer1$20
Bayer1$17
Lilly USA, LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 60th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$38,012
Medicare patients
100
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$24,252
EliquisApixaban13$19,102
OzempicSemaglutide11$11,303
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$4,376
Atorvastatin Calcium235$3,677
Losartan Potassium178$3,196
Levothyroxine Sodium137$2,425
Estradiol26$2,122
Lisinopril139$1,479
Gabapentin80$1,405
Omeprazole80$1,320
Tolterodine Tartrate ErTolterodine Tartrate11$1,175
Amlodipine Besylate126$1,120
Duloxetine Hcl46$1,103
Metoprolol Succinate38$996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$15$24,25220 claims
PfizerEliquis$20$19,10213 claims
Novo NordiskOzempic$298$11,30311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,657 family providers in Michigan.

Other family in Cadillac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →